Ziopharm appoints Kevin S. Boyle as CEO effective Aug 30, 2021; Heidi Hagen returns to Board

Alaunos Therapeutics, Inc.

Kevin S. Boyle named CEO and director; base salary $600K, target bonus 60%, sign-on bonus $50K.
Equity awards: option for 2,625,000 shares and 875,000 RSUs, each vesting over 4 years.
Heidi Hagen steps down as interim CEO, remains on Board (since June 2019).
Raffaele Baffa appointed Head of R&D in addition to CMO; Adam Levy named EVP Corp Dev & IR.
Boyle most recently CEO of Kuur Therapeutics, led $185M acquisition by Athenex in May 2021.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kevin S. Boyle, Sr.

Chief Executive Officer and Director

TCRT · Alaunos Therapeutics, Inc.

Effective: 2021-08-30
Filed: August 30, 2021, 7:59 PM ET

On August 22, 2021, the board of directors, or the Board, of ZIOPHARM Oncology, Inc., or the Company, appointed Kevin S. Boyle, Sr., age 48, as Chief Executive Officer of the Company, effective August 30, 2021.

Role change

Heidi Hagen

Interim Chief Executive Officer

TCRT · Alaunos Therapeutics, Inc.

Effective: 2021-08-30
Successor: Kevin S. Boyle, Sr.
Filed: August 30, 2021, 7:59 PM ET

Heidi Hagen, who has served as the Company’s Interim Chief Executive Officer since February 2021, will resign as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin S. Boyle, Sr. was appointed as Chief Executive Officer and Director at Alaunos Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer and Director

Exact text from the filing

On August 22, 2021, the board of directors, or the Board, of ZIOPHARM Oncology, Inc., or the Company, appointed Kevin S. Boyle, Sr., age 48, as Chief Executive Officer of the Company, effective August 30, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Heidi Hagen resigned as Interim Chief Executive Officer at Alaunos Therapeutics, Inc..

Action: resigned
Role: Interim Chief Executive Officer

Exact text from the filing

Heidi Hagen, who has served as the Company’s Interim Chief Executive Officer since February 2021, will resign as the Company’s Chief Executive Officer.

View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-260859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.